Note 6 - Investments	9 Months Ended
Sep. 30, 2013
Investments Schedule [Abstract]
Investment [Text Block]	Note F – Investments Immune Ltd. purchased 3,846,154shares of Pre-merged Immune Inc.’s common stock at a price of $0.13 per share, or $0.5 million, during the first nine months of 2013. These shares were not registered and were carried on the balance sheet at cost. These shares were purchased in contemplation of the Merger Agreement and were treated as a component of the consideration upon consummation of the merger. The Company is party to a related party loan pursuant to the merger agreement with Immune Ltd. The Company borrowed approximately $1.1 million from Immune Ltd. at September 30, 2013. The loan was bearing interest at a rate of 3.27%, which equates to an immaterial amount of interest expense through September 30, 2013. The loan was eliminated in consolidation upon the closing of the merger with Immune Ltd. on August 25, 2013.

Note 6 - Investments

9 Months Ended

Sep. 30, 2013

Note F – Investments

Immune Ltd. purchased 3,846,154shares of Pre-merged Immune Inc.’s common stock at a price of $0.13 per share, or $0.5 million, during the first nine months of 2013. These shares were not registered and were carried on the balance sheet at cost. These shares were purchased in contemplation of the Merger Agreement and were treated as a component of the consideration upon consummation of the merger.

The Company is party to a related party loan pursuant to the merger agreement with Immune Ltd. The Company borrowed approximately $1.1 million from Immune Ltd. at September 30, 2013. The loan was bearing interest at a rate of 3.27%, which equates to an immaterial amount of interest expense through September 30, 2013. The loan was eliminated in consolidation upon the closing of the merger with Immune Ltd. on August 25, 2013.